Companies › Acurx Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ibezapolstat (ACX-362E) Bacterial DNA topoisomerase inhibitor | – | Phase 2 | Clostridium Difficile Infection Recurrence | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07513285 | Ibezapolstat (ACX-362E) | Phase 2 | Clostridium Difficile Infection Recurrence | Infectious disease | Sep 2027 |
Cash of $11m on 2026-06-30; operating cash outflow about $6m a year; runway about 20 months at that burn, to Mar 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
60 Degrees Pharmaceuticals Lakewood-Amedex Traws Pharma Amplexd Therapeutics Sano Chemicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.